カテゴリ： GlobalData, スペイン, 企業調査

Pharma Mar SA (PHM)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013991
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スペイン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA (PHM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Merger 13
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 13
Licensing Agreements 14
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 14
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 15
Eczacibasi Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 17
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 18
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 19
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 20
TTY Biopharm Enters into Licensing Agreement with PharmaMar 21
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 22
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 23
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 24
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 25
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 26
Pharma Mar SA – Key Competitors 27
Pharma Mar SA – Key Employees 28
Pharma Mar SA – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year 31
Jul 26, 2017: Pharma Mar group reports first half financial results 32
Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 33
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 34
Oct 27, 2016: PharmaMar Group Reports 9M 2016 Financial Results 36
Jul 26, 2016: Pharma Mar Group Reports 1H 2016 Financial Results 37
Apr 28, 2016: PharmaMar Group Reports Q1 2016 Financial Results 38
Government and Public Interest 39
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 39
Product News 41
12/01/2016: PharmaMar presents positive results with its conjugated antibody MI130110 in CD13-experssing tumor-cells 41
06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 42
05/18/2016: Janssen to Present Data on Trabectedin at the 2016 American Society of Clinical Oncology Annual Meeting 43
05/06/2016: Early diagnosis, a multidisciplinary approach and access to new therapies, key in the treatment of ovarian cancer 44
04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46
04/14/2016: PharmaMar Announces Presentation on Plitidepsin at American Association for Cancer Research (AACR) Annual Meeting 2016 47
04/14/2016: PharmaMar Announces Presentation on PM1183 at American Association for Cancer Research (AACR) Annual Meeting 2016 48
04/14/2016: PharmaMar Announces Presentation on PM184 at American Association for Cancer Research (AACR) Annual Meeting 2016 49
04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 50
03/03/2016: Yondelis Approved for Sale in 6 Additional Countries 51
Product Approvals 52
Oct 28, 2016: The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin 52
Sep 22, 2016: PharmaMar submits MAA to EMA for Aplidin for the treatment of multiple myeloma 53
Clinical Trials 54
Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound –PM14- in Patients with Solid Tumors 54
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 55
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 56
Nov 28, 2016: PharmaMar Begins a Phase I studyof PM1183 in Japan for the Treatment of Solid Tumors 57
Nov 10, 2016: PharmaMar shows new clinical data on PM1183 (lurbinectedin) at CTOS 2016 58
Nov 10, 2016: PharmaMar shows new clinical data on Yondelis (trabectedin) at CTOS 2016 59
Oct 31, 2016: PharmaMar is present at the 16th International Gynecologic Cancer Society Meeting with new evidence on Yondelis 61
Oct 18, 2016: PharmaMar completes the patient recruitment for the “CORAIL” Phase III pivotal study with PM1183 62
Oct 10, 2016: PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 – Associated Metastatic Breast Cancer at the ESMO 2016 Congress 63
Oct 05, 2016: PharmaMar announces new clinical data on lurbinectedin (PM1183) to be presented at ESMO 2016 64
Oct 05, 2016: PharmaMar announces new clinical data on Yondelis to be presented at ESMO 2016 66
Aug 11, 2016: PharmaMar Announces the IDMCs Response on the CORAIL Trial Using PM1183 67
Aug 02, 2016: PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer 68
Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 69
May 20, 2016: PharmaMar begins a Phase I study of lurbinectedin in combination with irinotecan for the treatment of solid tumors 70
May 19, 2016: PharmaMar Announces New Data on PM1183 to be Presented at 2016 ASCO Annual Meeting 71
May 19, 2016: PharmaMar Announces New Data on Yondelis at 2016 ASCO Annual Meeting 72
May 19, 2016: PharmaMar reports positive results from the Phase I study of Aplidin (plitidepsin) in combination with bortezomib and dexamethasone in patients with multiple myeloma at the 2016 ASCO Annual Meeting 73
Mar 31, 2016: Aplidin shows positive results in pivotal Phase III clinical trial for multiple myeloma 74
Feb 26, 2016: PharmaMar initiates a Phase II trial with antitumour drug PM184 in advanced breast cancer 75
Feb 08, 2016: The Phase III Clinical Trial Using PM1183 in Treating Ovarian Cancer Continues Following the IDMC’s Positive Recommendation 76
Other Significant Developments 77
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 13
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 14
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 15
Eczacibasi Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 17
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 18
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 19
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 20
TTY Biopharm Enters into Licensing Agreement with PharmaMar 21
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 22
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 23
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 24
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 25
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 26
Pharma Mar SA, Key Competitors 27
Pharma Mar SA, Key Employees 28
Pharma Mar SA, Subsidiaries 29

★海外企業調査レポート[Pharma Mar SA (PHM)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • IDT Biologika GmbH-製薬・医療分野：企業M&A・提携分析
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a manufacturer of vaccines and bio-pharmaceuticals products. It offers services which include integrated development and manufacturing services in four major areas of animal health, vaccines, pharmaceuticals a …
  • BioRestorative Therapies Inc (BRTX)：企業の財務・戦略的SWOT分析
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • Herti AD：企業の戦略・SWOT・財務情報
    Herti AD - Strategy, SWOT and Corporate Finance Report Summary Herti AD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Pfleiderer Deutschland GmbH：企業の戦略的SWOT分析
    Pfleiderer Deutschland GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Aperam SA：企業の戦略・SWOT・財務情報
    Aperam SA - Strategy, SWOT and Corporate Finance Report Summary Aperam SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • SPR Therapeutics LLC：製品パイプライン分析
    Summary SPR Therapeutics LLC (SPR Therapeutics) is a medical device company that develops and commercializes neurostimulation based therapies and medical devices. The company develops and commercializes therapies for post-surgical pain, neuropathic pain, and musculoskeletal pain. It also provides pe …
  • Tecrea Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Tecrea Ltd (Tecrea) is a cell and tissue delivery technology for research and drug development applications. The company develops Nanocin reagents and ingredients support research and development in academic and industrial research labs. It develops Nanocin-plasmid and Nanocin-RNA kits that …
  • Aeterna Zentaris Inc (AEZS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company’s lead product, macimorelin, a ghrelin receptor agonist and orally-ac …
  • Ingram Micro Inc.：企業の戦略的SWOT分析
    Ingram Micro Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Kuraray Co Ltd (3405)：企業の財務・戦略的SWOT分析
    Kuraray Co Ltd (3405) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • MOIL Limited：企業の戦略・SWOT・財務情報
    MOIL Limited - Strategy, SWOT and Corporate Finance Report Summary MOIL Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Transcontinental Inc (TCL.A)：企業の財務・戦略的SWOT分析
    Transcontinental Inc (TCL.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Helsinn Healthcare SA：企業のM&A・事業提携・投資動向
    Helsinn Healthcare SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Helsinn Healthcare SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Nexter Group：企業の戦略・SWOT・財務情報
    Nexter Group - Strategy, SWOT and Corporate Finance Report Summary Nexter Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Reliance Capital Ltd：企業の戦略・SWOT・財務分析
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Press Association：企業の戦略・SWOT・財務情報
    Press Association - Strategy, SWOT and Corporate Finance Report Summary Press Association - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • The Swatch Group Ltd：企業の戦略・SWOT・財務情報
    The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report Summary The Swatch Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Finance Wales plc：企業のM&A・事業提携・投資動向
    Finance Wales plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finance Wales plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • United Utilities Group Plc (UU)：電力：M&Aディール及び事業提携情報
    Summary United Utilities Group PLC (United Utilities) is a provider of water and wastewater services. It gathers water from reservoirs, lakes, boreholes and streams; and collects and treats wastewater, and deposits it into rivers and sea. The company extracts water from Lake Vyrnwy in Wales for cust …
  • United Surgical Partners International Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary United Surgical Partners International Inc (United Surgical Partners) is a healthcare service provider that offers ambulatory surgical services. The center provides services in the therapeutical areas of orthopedic, pain management, gynaecology, general surgery, ear, nose, and throat, endosc …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆